Atrial Fibrillation Surgery Market Report

Global Atrial Fibrillation Surgery Market Size

The global atrial fibrillation surgery market size was valued at USD 2.91 billion in 2025 and the global market is forecasted to grow at a CAGR of 14.14% from 2026 to 2034 and reach USD 9.56 billion by 2034 from USD 3.32 billion in 2026.

Atrial fibrillation, also called AFib or AF, doubles the risk of death. In addition, it increases the risk of stroke five to seven times. The increasing awareness about different treatment processes of the atrial fibrillation condition is boosting the market growth. It is estimated that 1 of the nine people below the age of 60 is affected by atrial fibrillation, directly resulting in the demand for the treatment. Patients with atrial fibrillation live with an increased morbidity and mortality risk, thus giving rise to the need for atrial fibrillation.

MARKET DRIVERS

Y-O-Y growth in the incidence of atrial fibrillation is majorly propelling the global atrial fibrillation surgery market growth.

As per the Centers for Disease Prevention and Control (CDC), the prevalence of AFib is predicted to range between 2.7 million to 6.1 million. This value is forecasted to hit 12.1 million by 2030, estimated to provide significant growth to the global article fibrillation market. In addition, the rising cases of obesity, hypertension, and heart conditions are aiding the growth of the market. Furthermore, growing cardiac problems coupled with the rising demand for atrial fibrillation surgery are favoring the growth of the global market.

The growing prevalence of minimally invasive procedures boosts the market's growth rate. Increasing expenditures on healthcare are also propelling the market's demand. The cost of atrial fibrillation surgery is low; thus, the need for the procedure is considerable. In addition, tremendous technological advancements in atrial fibrillation surgery improve the patient's cure rate. 

The rising research and development in the atrial fibrillation surgery market and the mergers and acquisitions among key market players are anticipated to boost the global market growth. Several new trials are conducted, and product launches are initiated to help the market grow. For example, the latest trial, called the LeAAPS trial (left atrial appendage occlusion), in patients with cardiac surgery who might be at risk of a heart stroke. The safety and efficiency of the surgery are now under discussion with the researchers. Additionally, technologies like the pulsed field ablation technology released this year that allows safer and faster atrial ablation procedures are fuelling the growth rate of the global market. 

MARKET RESTRAINTS

However, rising complications in real-time applications are hindering global market growth. The high cost of treatment procedures is additionally degrading the revenue of the atrial fibrillation market. The increasing preference towards pharmacological drugs to replace surgical needs and depend on medicines to treat atrial fibrillation is expected to drive the growth of this market. 

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Surgical Procedure Insights

The catheter ablation procedure segment held the largest share of the global market in 2025 and is estimated to grow with the highest CAGR during the forecast period. Factors like increasing demand for non-pharmaceutical treatments, growing patient awareness, and improved healthcare groundwork significantly push the global atrial fibrillation surgery market.

By Product Insights

The catheter ablation surgical devices segment is expected to be the largest segment in the worldwide market and is likely to be the fastest-growing segment during the forecast period due to its high acceptance of surgical procedures. In addition, catheter ablation is a minimally invasive procedure, and it helps reduce irregular heartbeats (arrhythmia) in patients, further promoting the segment's expansion. It is the most preferred and the most commonly used method to help relieve atrial fibrillation when open heart surgery is not required. It helps the patients heal quickly and return to their healthy physical state.

However, the surgical ablation segment is also expected to be a close second to the growing market revenue. Even though the surgical ablation procedure is more invasive and majorly used in an open heart surgery setting, it is beneficial for surgeons to maintain stability during complex surgeries. Sometimes, surgical catheter only uses small incisions on the rib cage and is not overly invasive. In addition, the camera sent in during surgical catheter helps get a better understanding of the heart's situation, promoting growth for the market. 

REGIONAL ANALYSIS

The North American regional market had dominated the global atrial fibrillation surgery market in the recent past and is predicted to continue the same during the forecast period due to the availability of highly advanced healthcare infrastructure and the adoption of highly advanced technologies. In addition, the presence of high volumes and complicated healthcare substructure, massive patient awareness, and increasing healthcare expenditure levels are expanding the market size in this region. Therefore, the U.S. atrial fibrillation surgery market is projected to have a potential growth rate during the forecast period.

During the forecast period, the European market occupied the second largest market share in the atrial fibrillation surgery market. The market growth is due to the growing population of older people, which is one primary factor driving the market growth. The UK is the leading nation in the market due to growing incidences of atrial fibrillation and rising healthcare awareness, and Germany will show lucrative growth over the period due to the increasing economy and adoption of the latest technologies.

The Asia Pacific is expected to be the fastest-growing segment due to the large senior population with a high risk of heart disease. Regulatory policies in Asia-Pacific countries are more flexible and business-friendly. This is due to the ubiquity of less strict regulations and data needs. China's atrial fibrillation surgery market will grow at a healthy rate due to a huge patient pool and healthcare expenditure integrated with increasing awareness in people. Growth is due to a vast number of elderly people population who are prone to high risk of heart diseases in countries like China and India.

Latin America region is observed to have a steady growth in the atrial fibrillation surgery market. Brazil is the leading nation in this region. The increase in Brazil is due to the development of the healthcare sector. In addition, the prevalence of minimally non-invasive surgeries is escalating the growth rate of the market.

The Middle East & Africa region shows a significant growth rate due to the increasing awareness of people. South Africa will have a steady growth rate in the forthcoming years due to increasing knowledge of advanced treatment processes. The growth rate in Saudi Arabia is propelling due to increasing lifestyle changes and the growing obese population.

KEY MARKET PLAYERS

Some of the notable players operating the global atrial fibrillation surgery market include

• Thermo Fisher Scientific, Inc.
• G.E. Healthcare
• QIAGEN N.V.
• Life Technologies
• Agilent Technologies
• Roche
• PerkinElmer
• Affymetrix
• Illumina, Inc.
• Bio-Rad Laboratories
• Oxford Gene Technology
• Luminex Corporation

RECENT MARKET HAPPENINGS

• In October 2022, the first radiofrequency balloon ablation catheter by the name HELIOSTAR was launched in Europe by a med tech company which is a part of Johnson and Johnson called biosense Webster. The machine is designed to help make cardiac ablations more efficient and to help make the job easier for physicians.  
• In October 2022, an attempt is being made to create an ablation technology that does not cause any side effects like damage to areas other than the targetted in the heart by a technological company called Stem Tronics. In addition, a significant investigation device exemption trial is being performed to produce pulsed electric fields and target specific heart regions. 
• In October 2022, Heartbeam, a heart device manufacturing company, initiated the development of a heart device that can be connected to the patient's smartwatch for continuous monitoring of the heart in various patterns, including atrial fibrillation. The California-based company is creating this wearable device to make it easier for remote health monitoring systems. 
• In May 2020, the US FDA approved the next-generation CardioFocus Inc. HeartLight X3 Endoscopic ablation system to treat drug-refractory recurrent symptomatic paroxysmal atrial fibrillation. 

MARKET SEGMENTATION

This research report on the global atrial fibrillation surgery market has been segmented and sub-segmented based on the surgical procedure, product, and region.

By Surgical Procedure

• Catheter Ablation procedure
• Surgical Ablation
• Maze procedure

By Product

• Catheter Ablation
• Surgical Ablation

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa